bioAffinity Technologies, Inc.

Stocks

BIAF

US09076W3079

Delayed Nasdaq Other stock markets 18:12:48 27/07/2026 +04			5-day change	1st Jan Change
0.6899 ^USD	+4.55%		-1.29%	-41.53%

07-22	BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity?s Diagnostics for Asthma and COPD	CI
07-22	BioAffinity Technologies, Inc. - Special Call

Transcript : BioAffinity Technologies, Inc. - Special Call

Published on 06/17/2026 at 05:20 am +04 - Modified on 06/17/2026 at 08:05 am +04

S&P Capital IQ

Add MarketScreener to your sources

Presentation Operator Message
Operator (Operator)

Good evening, and welcome, everyone, to tonight's webinar event. Before we begin, just a few reminders to anyone who is new to the webinar. [Operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about bioAffinity Technologies, Inc.

07-22	BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity?s Diagnostics for Asthma and COPD	CI
07-22	BioAffinity Technologies, Inc. - Special Call
07-19	Certain Series B Convertible Preferred Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.	CI
07-19	Certain Options of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.	CI
07-19	Certain Warrants of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.	CI
07-19	Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.	CI
06-22	BioAffinity Technologies Reports Positive Preclinical Findings for Proprietary Gene Silencing Technology Targeting Squamous and Basal Skin Cancer Cells	CI
06-18	BioAffinity Technologies Closes $3.2 Million Public Offering	MT
06-17	BioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13%	MT
06-17	BioAffinity Technologies, Inc. - Special Call
05-27	Bioaffinity Technologies Receives Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using Cypath Lung Technology	CI
05-08	Bioaffinity Technologies Inc - Q1 2026 net loss $3.6 million or $0.81 per share	RE
05-08	BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-28	Bioaffinity Technologies Collaborates With Brooke Army Medical Center For Pilot Study On Asthma And COPD Diagnostics	CI
04-14	BioAffinity Technologies, Inc. Releases Clinical Case Study Demonstrating Cypath Lung Diagnostic Test Performance	CI